Alzheon to Present at the 2016 JMP Securities Life Sciences Conference

FRAMINGHAM, Mass.--(BUSINESS WIRE)-- Alzheon Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer, will present at the 2016 JMP Securities Life Sciences Conference on Wednesday, June 22, 2016, at 12:30 pm at the St. Regis Hotel in New York, NY.

About AlzheonAlzheon, Inc. is committed to developing innovative medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders. Our lead clinical candidate, ALZ-801, is a Phase 3-ready, first-in-class, small molecule oral inhibitor of amyloid aggregation and neurotoxicity – hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the safety and efficacy profile of the active compound tramiprosate, which has been tested in clinical trials involving over 2,000 Alzheimer’s patients. Our mission is to apply our clinical expertise and technology platform to develop novel therapeutics that make a difference in patients’ lives by directly addressing the underlying pathology of devastating neurodegenerative disorders.

For more information, please visit www.alzheon.com.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160616005352/en/

The Yates Network
Media Contact:
Kathryn Morris, 845‐635‐9828
[email protected]

Source: Alzheon, Inc.

You May Also Be Interested In

• Brandywine Realty Trust Announces Expiration of Tender Offer for the 2028 Notes
• New Crypto Pepeto Announces Crossing 41,000 Buyers Fast as the BNB Price Prediction Targets $1,755
• Video - CEO Clips: Metalero Mining Advances District-Scale Exploration Next to a World-Class Silver Mine